Effect and action methanism of budesonide and mesalazine in the treatment of active inflammatory bowel disease
10.13699/j.cnki.1001-6821.2015.16.011
- VernacularTitle:布地奈德和美沙拉嗪对活动期炎症性肠病的疗效及作用机制研究
- Author:
Xue-Yan WANG
1
;
Shu-Ping XIE
;
Zhi-Min SUO
;
Yu-Hua KANG
;
Ling YU
;
Chun-Sheng DING
;
Jiang-Hai ZHAO
;
Li-Ya ZHOU
Author Information
1. 河南大学 淮河医院 消化内科
- Keywords:
budesonide;
mesalamine;
active inflammatory bowel disease;
Th17 cells;
interleukin-23
- From:
The Chinese Journal of Clinical Pharmacology
2015;(16):1594-1596
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect and impact of Th17 cells and interleukin -23 ( IL -23 ) by the treatment of budesonide and mesalazine in active inflammatory bowel disease.Methods Sixty -six patients with active inflammatory bowel disease were randomly divided into control and treatment groups, each group was 33 cases.Patients in control group were treated with mesalazine 1 g, four times each day.Patients in treatment group was treated with budesonide 200 -1600 μg? d-1 on the basis of control group.The efficacy, Th17 cells and IL -23 levels were compared after two months treatment. Results Total effective rate of treatment group (93.93%) was significantly lower than the control group (67.67%, P<0.05).Th17 cells levels of mild, moderate, severe patients in treatment group were (2.05 ±0.36) , ( 2.59 ±1.09 ) , ( 3.48 ±2.05 ) , significantly lower than that in control group, which were (2.33 ±0.51), (3.26 ±1.23), (4.67 ±2.27) ( P <0.05); IL -23 levels in treatment group were (208.3 ±28.7), ( 619.4 ±34.5 ), ( 1276.8 ±59.7 ), significantly lower than that in control group ( 276.9 ± 34.8 ) , (698.3 ±47.8) , ( 1356.3 ±71.6 ) ( P <0.05 ) .Conclusion The clinical efficacy of budesonide and mesalazine for the treatment of active inflammatory bowel diseaseis was good, and can effectively reduce the level of Th17 cells and IL-23.
